Cardiol Therapeutics Inc. (CRDL)

Every figure this model derived for CRDL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 24,484 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 21,416,684 CashAndCashEquivalents 2025-12-31
current assets 23,501,840 CurrentAssets 2025-12-31
current liabilities 5,655,039 CurrentLiabilities 2025-12-31
equity 17,877,718 Equity 2025-12-31
ocf -23,854,650 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 726,401 RevenueFromInterest 2025-12-31
sbc 10,700,913 AdjustmentsForSharebasedPayments 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up CRDL on one particular measure came for.

RatioValue
current ratio4.16
current ratio reported4.16
dilution pct21.56
revenue growth-39.13
revenue growth per share-49.93
rule of 40-4763.28

What to be careful about

What this model itself distrusts about CRDL's figures. Written by the derivation as it ran, not added afterwards.